vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $20.1M, roughly 1.0× Arteris, Inc.). Sight Sciences, Inc. runs the higher net margin — -20.4% vs -42.2%, a 21.8% gap on every dollar of revenue. On growth, Arteris, Inc. posted the faster year-over-year revenue change (30.0% vs 6.9%). Arteris, Inc. produced more free cash flow last quarter ($3.0M vs $-2.0M). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs 2.9%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
AIP vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $20.4M |
| Net Profit | $-8.5M | $-4.2M |
| Gross Margin | 90.8% | 87.3% |
| Operating Margin | -42.0% | -18.0% |
| Net Margin | -42.2% | -20.4% |
| Revenue YoY | 30.0% | 6.9% |
| Net Profit YoY | -3.7% | 64.9% |
| EPS (diluted) | $-0.19 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $20.4M | ||
| Q3 25 | $17.4M | $19.9M | ||
| Q2 25 | $16.5M | $19.6M | ||
| Q1 25 | $16.5M | $17.5M | ||
| Q4 24 | $15.5M | $19.1M | ||
| Q3 24 | $14.7M | $20.2M | ||
| Q2 24 | $14.6M | $21.4M | ||
| Q1 24 | $12.9M | $19.3M |
| Q4 25 | $-8.5M | $-4.2M | ||
| Q3 25 | $-9.0M | $-8.2M | ||
| Q2 25 | $-9.1M | $-11.9M | ||
| Q1 25 | $-8.1M | $-14.2M | ||
| Q4 24 | $-8.2M | $-11.8M | ||
| Q3 24 | $-7.7M | $-11.1M | ||
| Q2 24 | $-8.3M | $-12.3M | ||
| Q1 24 | $-9.4M | $-16.3M |
| Q4 25 | 90.8% | 87.3% | ||
| Q3 25 | 89.9% | 86.4% | ||
| Q2 25 | 89.4% | 84.8% | ||
| Q1 25 | 90.8% | 86.2% | ||
| Q4 24 | 89.8% | 86.8% | ||
| Q3 24 | 90.1% | 83.9% | ||
| Q2 24 | 90.0% | 85.8% | ||
| Q1 24 | 88.7% | 85.5% |
| Q4 25 | -42.0% | -18.0% | ||
| Q3 25 | -50.1% | -39.7% | ||
| Q2 25 | -50.0% | -59.6% | ||
| Q1 25 | -46.6% | -79.2% | ||
| Q4 24 | -45.9% | -62.5% | ||
| Q3 24 | -53.8% | -55.7% | ||
| Q2 24 | -51.1% | -59.2% | ||
| Q1 24 | -70.5% | -76.4% |
| Q4 25 | -42.2% | -20.4% | ||
| Q3 25 | -51.6% | -41.0% | ||
| Q2 25 | -55.3% | -61.0% | ||
| Q1 25 | -49.1% | -80.8% | ||
| Q4 24 | -53.0% | -62.1% | ||
| Q3 24 | -52.2% | -54.9% | ||
| Q2 24 | -57.2% | -57.7% | ||
| Q1 24 | -72.6% | -84.4% |
| Q4 25 | $-0.19 | $-0.07 | ||
| Q3 25 | $-0.21 | $-0.16 | ||
| Q2 25 | $-0.22 | $-0.23 | ||
| Q1 25 | $-0.20 | $-0.28 | ||
| Q4 24 | $-0.19 | $-0.23 | ||
| Q3 24 | $-0.20 | $-0.22 | ||
| Q2 24 | $-0.22 | $-0.25 | ||
| Q1 24 | $-0.25 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $-14.6M | $63.9M |
| Total Assets | $115.0M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $92.0M | ||
| Q3 25 | $39.0M | $92.4M | ||
| Q2 25 | $38.0M | $101.5M | ||
| Q1 25 | $42.3M | $108.8M | ||
| Q4 24 | $43.8M | $120.4M | ||
| Q3 24 | $48.7M | $118.6M | ||
| Q2 24 | $45.8M | $118.2M | ||
| Q1 24 | $44.8M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $-14.6M | $63.9M | ||
| Q3 25 | $-11.4M | $64.3M | ||
| Q2 25 | $-7.5M | $70.0M | ||
| Q1 25 | $-4.8M | $77.6M | ||
| Q4 24 | $-1.2M | $87.5M | ||
| Q3 24 | $2.2M | $95.0M | ||
| Q2 24 | $5.3M | $101.6M | ||
| Q1 24 | $9.5M | $109.2M |
| Q4 25 | $115.0M | $115.3M | ||
| Q3 25 | $107.7M | $116.3M | ||
| Q2 25 | $106.9M | $122.0M | ||
| Q1 25 | $98.3M | $129.7M | ||
| Q4 24 | $106.1M | $142.8M | ||
| Q3 24 | $97.7M | $143.6M | ||
| Q2 24 | $96.4M | $149.7M | ||
| Q1 24 | $101.4M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-1.8M |
| Free Cash FlowOCF − Capex | $3.0M | $-2.0M |
| FCF MarginFCF / Revenue | 15.1% | -9.7% |
| Capex IntensityCapex / Revenue | 0.7% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-1.8M | ||
| Q3 25 | $3.2M | $-8.7M | ||
| Q2 25 | $-2.5M | $-7.5M | ||
| Q1 25 | $2.9M | $-11.6M | ||
| Q4 24 | $-2.6M | $-3.5M | ||
| Q3 24 | $1.1M | $362.0K | ||
| Q2 24 | $311.0K | $-9.5M | ||
| Q1 24 | $477.0K | $-9.8M |
| Q4 25 | $3.0M | $-2.0M | ||
| Q3 25 | $2.5M | $-8.9M | ||
| Q2 25 | $-2.8M | $-7.8M | ||
| Q1 25 | $2.7M | — | ||
| Q4 24 | $-2.7M | $-3.6M | ||
| Q3 24 | $1.1M | $311.0K | ||
| Q2 24 | $264.0K | $-9.5M | ||
| Q1 24 | $281.0K | $-9.9M |
| Q4 25 | 15.1% | -9.7% | ||
| Q3 25 | 14.2% | -44.7% | ||
| Q2 25 | -17.2% | -39.6% | ||
| Q1 25 | 16.2% | — | ||
| Q4 24 | -17.3% | -18.9% | ||
| Q3 24 | 7.4% | 1.5% | ||
| Q2 24 | 1.8% | -44.7% | ||
| Q1 24 | 2.2% | -51.4% |
| Q4 25 | 0.7% | 0.8% | ||
| Q3 25 | 4.1% | 0.9% | ||
| Q2 25 | 2.2% | 1.1% | ||
| Q1 25 | 1.1% | 0.0% | ||
| Q4 24 | 0.3% | 0.7% | ||
| Q3 24 | 0.2% | 0.3% | ||
| Q2 24 | 0.3% | 0.4% | ||
| Q1 24 | 1.5% | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
